Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma 2019-12-10 11:38
Townsville Hospital Treats First Australian Patient With Elekta Unity MR-Linac, a Transformative Approach to Precision Radiation Therapy 2019-12-10 08:13
Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies 2019-12-09 22:00
Hebron Announces $6.5 Million Private Placement 2019-12-09 21:30
BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors 2019-12-09 21:00
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial 2019-12-06 18:53
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China 2019-12-06 08:00
Suvoda Secures $40M Investment from LLR Partners 2019-12-05 17:00
Mayapada Clinic Accomplished Plenary Level Certification from the Accreditation Commission of the Ministry of Health 2019-12-05 13:17
Biocon Biologics Takes Forward its Mission to Unlock Universal Access to Insulins Globally 2019-12-05 09:00
FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa 2019-12-04 19:22
Merck and Ping An Good Doctor Form Strategic Collaboration to Advance Intelligent Healthcare in China 2019-12-04 12:57
Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection - Lumosa to Initiate the Bridging Study in the US 2019-12-03 17:36
Continuing the Resplendence with 20 Years' Glory, CPhI China Welcomes the Golden Year of Chinese Pharma 2019-12-03 16:54
New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority 2019-12-03 05:30
Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly 2019-12-02 09:37
Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements 2019-12-02 08:00
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication 2019-11-29 20:22
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout 2019-11-29 08:00
Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL) 2019-11-28 12:10
1 299 300 301 302 303 401